International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 4, April 2025 ijppr.humanjournals.com ISSN: 2349-7203

A Comprehensive Review of Alzheimer's Disease: Pathophysiology, Diagnosis, and Emerging Therapies

Anshika Sharma, Vishal Vijay Patil

KC Institute of Pharmaceutical Sciences, Una, India.

Received: 2025-4-05 Revised: 2025-4-17 Accepted: 2025-4-25

ABSTRACT

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. It is characterized by the accumulation of β-amyloid plaques and neurofibrillary tangles, leading to neuronal loss, cognitive decline, and functional impairment. This paper provides a comprehensive review of AD, covering its pathophysiology, genetic and environmental risk factors, diagnostic methods, and current treatment strategies. While no cure exists, recent advancements in disease-modifying therapies, such as monoclonal antibodies targeting amyloid pathology, offer new hope for managing the disease. Additionally, lifestyle interventions, neuroprotective strategies, and emerging research on tau-targeting therapies and precision medicine are explored. The paper emphasizes the importance of early diagnosis, biomarker discovery, and innovative treatment approaches to combat the growing global burden of AD.

INTRODUTION

Definition of Alzheimer's Disease (AD) :

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory impairment, cognitive decline, and functional disability. It is the most common cause of dementia, accounting for approximately 60–80% of dementia cases worldwide (1). The disease is pathologically defined by the presence of β-amyloid (Aβ) plaques, neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, neuroinflammation, and neuronal loss, leading to synaptic dysfunction and brain atrophy (2).

AD progresses through different stages, beginning with mild cognitive impairment (MCI) and advancing to severe dementia. While the exact etiology of AD remains unclear, multiple genetic, environmental, and lifestyle factors contribute to disease onset and progression. A major genetic risk factor for late-onset AD (LOAD) is the Apolipoprotein E (APOE) ε4 allele (3). Additionally, mutations in APP (Amyloid Precursor Protein), PSEN1, and PSEN2 (Presenilin 1 and 2) are linked to early-onset familial AD (EOFAD), supporting the amyloid cascade hypothesis, which suggests that Aβ accumulation is the primary driver of AD pathology (4). Other contributors include oxidative stress, mitochondrial dysfunction, vascular pathology, and neuroinflammation (5).

Despite significant research advances, there is currently no cure for AD. However, the approval of disease-modifying therapies (DMTs), such as aducanumab (2021) and lecanemab (2023), represents a major breakthrough in targeting amyloid pathology rather than just managing symptoms (6).



Types of Alzheimer's Disease :

There are three types or severities of Alzheimer's disease, which we outline (Husebo et al., 2016).

Mild Alzheimer's :

At this stage, patients encounter difficulties doing daily chores such as work tasks and bill payments, among other things. These symptoms are not very serious, but at this stage, patients can work with some difficulty; they take longer than usual to complete everyday tasks, which they used to do with ease previously.

Moderate Alzheimer's :

Patients in this stage are more vulnerable to neuronal damage, resulting in more severe Alzheimer's disease symptoms. Because of the memory loss, the confusion worsens and they require assistance from others. These individuals, despite their physical agility, are unable to accomplish everyday activities because their delusions take over the sensory processing of their thinking.

Severe Alzheimer's :

The brain cells start dying as the plaques and tangles spread, reducing the brain tissue's size. Patients with this condition usually stay in bed and cannot communicate normally. Symptom Stages of Alzheimer's Disease Generally, the symptoms of Alzheimer's disease are divided into three main stages (Kim et al., 2021).

Early Symptoms :

Memory loss is the primary symptom of Alzheimer's disease in its early stages. For instance, forgetting the names of places and items, having trouble finding the correct term, and continuously asking inquiries. Increased anxiety, moments of bewilderment, and behavioral abnormalities are also prevalent.

Middle-Stage Symptoms :

Memory issues will worsen as Alzheimer's disease progresses. Some patients in this stage may struggle to remember the names of people they know and not recognize family and friends. At this stage, some Alzheimer's patients typically require assistance with daily living activities from others. They may require assistance with eating, washing, dressing, and using the toilet.

Later Symptoms :

Alzheimer's symptoms will worsen as the disease progresses, which can be worrisome for patients, carers, friends, and family. Delusions and paranoia may occur and fade during the disease, but they might intensify as it advances. People with advanced Alzheimer's disease may require full-time care and assistance with eating, moving, and personal care.

Historical Background of Alzheimer's Disease :

Early Discoveries (1906–1910) :

Alzheimer's disease was first described in 1906 by Dr. Alois Alzheimer, a German psychiatrist and neuropathologist. He presented the case of Auguste Deter, a 51-year-old woman suffering from severe memory loss, confusion, paranoia, and progressive cognitive decline (7). After her death, Alzheimer conducted a postmortem examination and discovered unusual pathological structures in her brain—now recognized as β-amyloid plaques and neurofibrillary tangles. In 1910, Alzheimer's colleague, Emil Kraepelin, officially named the condition "Alzheimer's disease" in his psychiatric textbook, distinguishing it from other forms of dementia (8).

Recognition as a Major Cause of Dementia (1960s–1980s) :

For much of the 20th century, AD was thought to be a rare disorder affecting middle-aged individuals. However, in the 1960s, researchers found that the same neuropathological changes observed in early-onset cases were also present in elderly individuals with senile dementia (9). This led to the recognition that AD is the leading cause of dementia in aging populations.

By the 1980s, scientific advancements identified β-amyloid plaques and neurofibrillary tangles as key pathological markers of AD. Additionally, researchers discovered that acetylcholine deficiency played a role in cognitive decline, leading to the development of cholinesterase inhibitors, the first class of drugs used to manage AD symptoms.

Genetic and Molecular Advances (1990s–2000s) :

The 1990s saw major breakthroughs in genetic research. Scientists discovered mutations in APP, PSEN1, and PSEN2 genes, which were linked to early-onset familial AD (EOFAD), reinforcing the amyloid hypothesis (4). Additionally, researchers identified the APOE ε4 allele as a major genetic risk factor for late-onset AD (LOAD) (3). During this period, neuroimaging techniques such as positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers allowed for earlier and more accurate diagnosis of AD. These discoveries set the foundation for biomarker-driven research and clinical trials.

Modern Developments and Treatment Advances (2010s–Present) :

In the 2010s, research expanded beyond amyloid plaques to include tau pathology, neuroinflammation, and synaptic dysfunction as key contributors to AD progression. This led to the development of disease-modifying therapies (DMTs) aimed at slowing disease progression.

In 2021, the FDA approved aducanumab, the first monoclonal antibody targeting amyloid plaques. In 2023, lecanemab was approved, further advancing anti-amyloid therapy (1). Despite these developments, AD remains an incurable disease, and ongoing research continues to explore new therapeutic targets, including tau-based treatments, neuroinflammation inhibitors, and gene therapies.

Prevalence and Global Impact of Alzheimer's Disease :

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60–70% of cases (13). It is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral changes, ultimately leading to significant disability and dependency among affected individuals (13). As the global population ages, the prevalence and burden of AD are expected to increase substantially.

Prevalence and Incidence :

As of 2020, over 55 million people worldwide were living with dementia, with Alzheimer's disease being the leading cause (10). The number of individuals with dementia is projected to nearly double every 20 years, reaching 78 million in 2030 and 139 million by 2050 (10).

The incidence of Alzheimer's disease and other dementias has risen significantly over the past three decades. From 1990 to 2019, the global incidence of dementia increased by 147.95%, from 2.92 million cases in 1990 to 7.24 million cases in 2019 (11). In 2019, an estimated 57 million people worldwide were living with dementia, and this number is projected to grow to 153 million by 2050 (12).

Regional Distribution :

The burden of Alzheimer's disease is not equally distributed across the world. Currently, around 60% of people with dementia live in low- and middle-income countries (LMICs), and this figure is expected to increase to 71% by 2050 (10). In these regions, limited healthcare infrastructure and resources exacerbate the challenges of managing AD.

Mortality and Disability Burden :

Dementia, including Alzheimer's disease, is the seventh leading cause of death globally and one of the leading causes of disability among older adults (13). AD significantly impacts quality of life, and its progressive nature leads to increasing levels of dependency and long-term care needs (12).

Economic Impact :

The global economic burden of Alzheimer's disease and other dementias is substantial. In 2019, dementia care costs were estimated at $1.3 trillion and are projected to exceed $2.8 trillion by 2030 due to rising prevalence and healthcare demands (14). Over the period 2020–2050, Alzheimer's disease is expected to cost the global economy approximately $14.5 trillion (11).

Impact on Caregivers and Society :

Caring for individuals with Alzheimer's disease places a significant emotional, physical, and financial burden on families and caregivers. Many experience psychological distress, social isolation, and physical health challenges due to the demands of long-term care (Brodaty & Donkin, 2009). Additionally, AD contributes to high hospitalization rates and long-term care costs, straining healthcare systems worldwide (12).

Importance of Research in Alzheimer's Disease :

Alzheimer's disease (AD) is a major public health challenge, affecting millions worldwide and placing a substantial burden on individuals, families, and healthcare systems. Despite its growing prevalence, there is currently no cure for AD, and existing treatments only provide symptomatic relief (12). Research in Alzheimer's disease is crucial for understanding its underlying mechanisms, developing effective treatments, and improving the quality of life for those affected.

1. Advancing Understanding of Disease Mechanisms :

Research has significantly advanced our understanding of the pathological processes involved in AD, including amyloid-beta plaque accumulation, tau protein tangles, neuroinflammation, and neuronal loss (13). Studying these mechanisms is essential for identifying new therapeutic targets and developing disease-modifying treatments. Emerging research also suggests that genetic and environmental factors contribute to AD risk, highlighting the need for further investigation (14).

2. Development of Effective Treatments and Potential Cures :

Currently available treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, provide only temporary symptomatic relief (15). Ongoing research aims to develop disease-modifying therapies that target underlying pathological processes, such as monoclonal antibodies against amyloid-beta (e.g., aducanumab and lecanemab) and tau protein inhibitors (16). Additionally, stem cell therapy and gene therapy are being explored as potential future interventions (17).

3. Early Diagnosis and Biomarker Discovery :

Early detection of AD is critical for timely intervention and better disease management. Research on biomarkers, such as cerebrospinal fluid (CSF) and blood-based markers for amyloid-beta, tau, and neurodegeneration, has improved diagnostic accuracy (Hampel et al., 2021). Advances in neuroimaging, including PET and MRI techniques, allow for earlier and more precise diagnosis, even before clinical symptoms appear (13).

4. Prevention Strategies and Risk Reduction :

Lifestyle and preventive strategies are becoming a major focus of AD research. Studies have identified modifiable risk factors, including cardiovascular health, diet, physical activity, cognitive engagement, and social interaction (18). Research-based interventions, such as the FINGER study, have shown that multi-domain lifestyle interventions can reduce dementia risk (19).

5. Impact on Caregiving and Healthcare Policies :

Alzheimer's research is essential for improving caregiving strategies and healthcare policies. Studies on caregiver burden, mental health, and social support systems help develop programs that provide better resources for families and healthcare providers (Brodaty & Donkin, 2009). Research also informs policy decisions on healthcare funding, long-term care models, and global dementia action plans (20).

6. Economic and Societal Benefits of Research Investment :

Investing in AD research can lead to significant economic benefits by reducing healthcare costs and improving patient outcomes. The global cost of dementia care is projected to exceed $2.8 trillion by 2030 (21). Research-driven advances in prevention, early diagnosis, and treatment could significantly reduce this burden, making investment in AD research a critical public health priority (20).

2. Pathophysiology of Alzheimer's Disease :

Alzheimer's disease (AD) is a **multifactorial neurodegenerative disorder** involving **molecular, cellular, and biochemical abnormalities**. The disease is characterized by **progressive neuronal loss, synaptic dysfunction, and brain atrophy**, primarily affecting the **hippocampus, entorhinal cortex, and neocortex**. The three primary **pathophysiological mechanisms** of AD include:

1. **Neuropathological hallmarks** (Aβ plaques, tau tangles, and neuroinflammation).
2. **Neurotransmitter dysfunction** (cholinergic and other systems).
3. **Genetic and environmental risk factors** (APOE and lifestyle influences).

2.1 Neuropathological Hallmarks :

2.1.1 Amyloid-Beta (Aβ) Plaques :

Aβ plaques are **extracellular protein aggregates** derived from **amyloid precursor protein (APP)**. The formation of Aβ occurs via sequential cleavage of APP by **β-secretase (BACE1) and γ-secretase**, producing **Aβ peptides (Aβ40 and Aβ42)** (22). Aβ42 is particularly **aggregation-prone**, forming toxic **oligomers, fibrils, and ultimately amyloid plaques** (23).

Aβ accumulation triggers:

- **Synaptic dysfunction and neuronal toxicity** (24).
- **Oxidative stress and mitochondrial damage** (25).
- **Disruption of calcium homeostasis**, leading to **excitotoxicity** (26).
- **Microglial activation and neuroinflammation**, promoting **chronic neuronal damage** (27).

2.1.2 Neurofibrillary Tangles (Tau Protein) :

Neurofibrillary tangles (NFTs) are composed of **hyperphosphorylated tau protein**, which normally functions as a **microtubule-associated protein (MAP)** supporting **axonal transport** (28). In AD, tau undergoes **hyperphosphorylation**, leading to its **detachment from microtubules**, aggregation into **paired helical filaments (PHFs)**, and formation of NFTs (29).

Tau pathology leads to:

- **Disruption of neuronal transport and synaptic dysfunction** (30).
- **Spreading of tau aggregates between neurons**, promoting disease progression (31).
- **Direct neuronal toxicity and apoptosis** (32).

2.1.3 Neuroinflammation and Glial Cell Involvement :

Chronic neuroinflammation is a critical factor in AD, involving **activated microglia, astrocytes, and dysregulated immune responses**.

- **Microglial activation :**

  - Microglia attempt to clear Aβ deposits but become **chronically activated**, releasing **pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)** (33).
  - Dysfunctional **TREM2 mutations** impair microglial Aβ clearance, increasing plaque burden (34).

- **Astrocytes and blood-brain barrier (BBB) dysfunction :**

- Reactive astrocytes contribute to **glutamate excitotoxicity** and **impaired neuroprotection** (35).
- BBB breakdown allows infiltration of **peripheral immune cells**, exacerbating inflammation (36).

- **Complement system dysregulation :**
  - Excessive **C1q and C3 activation** results in **synaptic pruning**, leading to **early synapse loss** and cognitive decline (37).

2.2 Neurotransmitter Dysfunction :

2.2.1 Role of Acetylcholine (Cholinergic Hypothesis) :

The **cholinergic hypothesis** suggests that **acetylcholine (ACh) deficiency** is a primary cause of cognitive decline in AD (38).

- **Reduction in choline acetyltransferase (ChAT) activity** leads to impaired ACh synthesis (39).
- Loss of **basal forebrain cholinergic neurons**, particularly in the **nucleus basalis of Meynert**, reduces ACh levels in the **hippocampus and cortex** (40).
- Acetylcholinesterase inhibitors (**donepezil, rivastigmine, galantamine**) are used to **enhance cholinergic function** and improve cognition (41).

2.2.2 Other Neurotransmitter Systems Involved :

- **Glutamate excitotoxicity** (NMDA receptor dysfunction) :
  - Overactivation of **NMDA receptors by excess glutamate** leads to **Ca^{2+} influx, oxidative stress, and neuronal death** (42).
  - NMDA receptor antagonist **memantine** is used to prevent **glutamate-induced toxicity** (43).
- **Serotonergic and noradrenergic dysfunction :**
  - **Reduced serotonin levels** in the raphe nuclei contribute to **depression and mood disturbances** in AD (44).
  - **Noradrenaline loss from the locus coeruleus** affects **cognitive flexibility and attention** (45).

2.3 Genetic and Environmental Risk Factors :

2.3.1 APOE Gene and Other Genetic Factors :

The **Apolipoprotein E (APOE) gene** is the strongest genetic risk factor for late-onset AD.

- **APOE ε4 allele** carriers have **increased Aβ aggregation and reduced clearance**, promoting plaque formation (46).
- **APOE ε2 allele** is protective against AD (47).

Other genetic mutations linked to AD include :

- **APP (Amyloid Precursor Protein) mutations**, increasing Aβ production (48).
- **PSEN1 and PSEN2 (Presenilin 1 and 2) mutations**, affecting γ-secretase function, leading to early-onset AD (49).

2.3.2 Lifestyle and Environmental Influences :

- **Cardiovascular risk factors:** Hypertension, diabetes, and hypercholesterolemia increase AD risk (50).
- **Physical inactivity and poor diet:** Mediterranean diet and exercise reduce AD risk (51).

- **Sleep disturbances:** Impaired sleep accelerates Aβ accumulation (52).
- **Social and cognitive engagement:** Higher education and social interactions lower AD risk (53).

3. Diagnosis of Alzheimer's Disease :

Alzheimer's disease (AD) is diagnosed based on **clinical assessment, biomarkers, and neuroimaging techniques**. Early diagnosis is critical for timely intervention and management. The diagnostic process follows **a multi-step approach**, including **clinical staging, biomarker evaluation, and neuroimaging**.

3.1. Clinical Presentation and Stages :

AD progresses through distinct clinical stages, beginning with **Mild Cognitive Impairment (MCI)** and advancing to **severe dementia**. These stages are classified based on **cognitive decline, functional impairment, and behavioral symptoms** (54).

3.1.1 Mild Cognitive Impairment (MCI) :

- MCI represents a transitional stage between **normal aging and AD** (55).
- Individuals with MCI exhibit **memory impairment** beyond expected age-related changes but maintain **independent daily function**.
- About **10-15% of MCI cases progress to AD annually** (56).

3.1.2 Early-Stage AD :

- **Mild memory loss**, especially **episodic memory deficits** (e.g., forgetting recent events).
- Difficulty with **word-finding (anomia)** and **problem-solving**.
- **Preserved social skills**, though subtle personality changes may appear (57).

3.1.3 Moderate-Stage AD :

- **Worsening cognitive deficits**: impaired reasoning, spatial disorientation, and executive dysfunction.
- **Behavioral changes**: agitation, depression, and sleep disturbances (58).
- **Difficulty with daily activities**: dressing, cooking, and managing finances.

3.1.4 Late-Stage AD :

- **Severe cognitive decline**: loss of recognition of family members, speech difficulties.
- **Complete dependency** for daily living activities.
- **Motor dysfunction**: rigidity, difficulty swallowing, and immobility.

The **Clinical Dementia Rating (CDR)** scale and the **Mini-Mental State Examination (MMSE)** are commonly used for staging AD (59).

3.2 Biomarkers and Diagnostic Techniques :

Biomarkers play a crucial role in **confirming AD pathology** before significant cognitive decline occurs. The **National Institute on Aging–Alzheimer's Association (NIA-AA)** introduced the **AT(N) framework**, which categorizes biomarkers into:

- **A (Amyloid pathology)**: Aβ42/Aβ40 ratio.
- **T (Tau pathology)**: Total tau (t-tau) and phosphorylated tau (p-tau).
- **N (Neurodegeneration)**: Structural MRI, FDG-PET, and blood-based markers (13).

3.2.1 Cerebrospinal Fluid (CSF) Biomarkers :

- **Aβ42 levels decrease** in CSF due to aggregation into plaques (60).
- **Increased CSF tau and p-tau** reflect neuronal damage and NFT pathology (61).
- **CSF biomarkers have high diagnostic accuracy (~85-90%)**, distinguishing AD from other dementias (62).

3.2.2 Neuroimaging Techniques :

Magnetic Resonance Imaging (MRI)

- Identifies **hippocampal atrophy**, a hallmark of early AD (63).
- Tracks disease progression by measuring **cortical thinning** and **ventricular enlargement**.

Positron Emission Tomography (PET) Scans :

- **Amyloid PET (e.g., PiB, florbetapir)** detects Aβ deposition in vivo (64).
- **Tau PET (e.g., flortaucipir)** identifies NFT burden in later disease stages (65).
- **FDG-PET** assesses **glucose metabolism**, showing hypometabolism in **parietal and temporal lobes** in AD (66).

3.2.3 Blood-Based Biomarkers :

- **Plasma Aβ42/40 ratio**: Reflects amyloid pathology, though less accurate than CSF (67).
- **Plasma p-tau181 and p-tau217**: Emerging as highly sensitive and specific for AD (68).
- **Neurofilament Light Chain (NfL)**: Indicates **neuronal injury** and correlates with disease severity (69).

3.3 Advances in Early Detection :

Early and **preclinical** detection of AD is a key research focus. Advances in **artificial intelligence (AI), machine learning, and novel biomarker discoveries** have improved diagnostic accuracy.

3.3.1 AI and Machine Learning in Diagnosis :

- **AI-based algorithms analyze MRI, PET, and blood biomarkers**, improving diagnostic precision (70).
- **Deep learning models detect subtle atrophy patterns** in early-stage AD (71).
- AI-enhanced **speech analysis** can identify linguistic impairments linked to AD (72).

3.3.2 Novel Biomarker Discoveries :

- **Synaptic biomarkers (neurogranin, SNAP-25)** indicate synaptic dysfunction in AD (73).
- **Exosomal biomarkers** in blood and CSF predict **Aβ and tau pathology** (74).

- **Retinal imaging techniques** detect amyloid deposits **non-invasively** (75).

4. Current Treatment Strategies for Alzheimer's Disease :

There is currently **no cure for Alzheimer's disease (AD)**, but **approved medications and non-pharmacological approaches** help manage symptoms and slow disease progression. Current treatments fall into two categories :

1. **Symptomatic treatments** – address cognitive and behavioral symptoms without altering disease progression.

2. **Disease-modifying treatments** – aim to slow or halt the underlying neurodegenerative processes.

4.1. FDA-Approved Medications :

The U.S. Food and Drug Administration (FDA) has **approved several drugs** to manage AD symptoms. These drugs primarily target **cholinergic and glutamatergic neurotransmitter systems** to improve cognitive function.

4.1.1 Cholinesterase Inhibitors (ChEIs) :

Cholinesterase inhibitors **increase acetylcholine (ACh) levels** by inhibiting the **acetylcholinesterase enzyme**, which breaks down ACh in the synaptic cleft. These drugs are **most effective in mild to moderate AD** (75).

Drug	Indication	Mechanism of Action	Side Effects
Donepezil	Mild, moderate, and severe AD	Reversibly inhibits acetylcholinesterase	Nausea, diarrhea, insomnia
Rivastigmine	Mild to moderate AD	Inhibits both acetylcholinesterase and butyrylcholinesterase	Gastrointestinal (GI) upset, dizziness
Galantamine	Mild to moderate AD	Inhibits acetylcholinesterase and modulates nicotinic receptors	Nausea, weight loss
Memantine	Moderate to severe AD	Blocks excessive glutamate activity at NMDA receptors to prevent excitotoxicity	Dizziness, confusion, headache

Effectiveness :

- ChEIs provide **modest cognitive benefits**, delaying symptom progression by **6-12 months** (75).
- They **do not halt neurodegeneration**, making them **purely symptomatic treatments**.
- Memantine provides **modest improvements in cognition and daily function**.
- Works **synergistically** with cholinesterase inhibitors for **enhanced benefits** (76).

4.1.2 NMDA Receptor Antagonists :

Memantine is an **N-methyl-D-aspartate (NMDA) receptor antagonist**, approved for **moderate to severe AD**.

4.1.3 Anti-Amyloid Therapies (Disease-Modifying Drugs) :

Recently, the **first disease-modifying therapies** targeting **amyloid-beta (Aβ)** have been approved:

Drug	Indication	Mechanism of Action	Approval Year
Aducanumab (Aduhelm)	Mild cognitive impairment (MCI) & early AD	Anti-Aβ monoclonal antibody clearing amyloid plaques	FDA 2021 (Controversial)
Lecanemab (Leqembi)	Early AD	Reduces Aβ aggregation and plaques	FDA 2023

Effectiveness & Controversies :

- **Aducanumab & Lecanemab** showed **reduction in Aβ plaques**, but **clinical benefits are modest**.
- Concerns about **ARIA (Amyloid-Related Imaging Abnormalities)**—brain swelling and microhemorrhages (77).

4.2. Symptomatic vs. Disease-Modifying Treatments :

4.2.1 Limitations of Current Symptomatic Therapies :

- ChEIs and memantine **do not stop disease progression**.
- Effectiveness **declines as neurodegeneration advances**.
- **Side effects (nausea, dizziness, GI issues)** can limit adherence.

4.2.2 Challenges in Developing Disease-Modifying Treatments :

Developing **disease-modifying drugs** for AD is highly challenging due to:

1. Complex Pathophysiology :

- AD involves **amyloid plaques, tau tangles, neuroinflammation, and synaptic dysfunction** (78).
- Targeting **a single mechanism** (e.g., amyloid clearance) **may not be sufficient**.

2. Difficulty in Early Diagnosis :

- By the time **clinical symptoms appear**, **significant neuronal loss** has already occurred.
- **Early-stage intervention is crucial**, requiring **preclinical diagnosis methods**.

3. Clinical Trial Challenges :

- High **failure rates**: 99.6% of AD drugs have failed between 2002-2012 (Cummings et al., 2014).
- **Long study durations**: Disease progression takes **years**, making trials costly and time-consuming.
- **Heterogeneity of AD**: Genetic and lifestyle factors make it difficult to develop a **"one-size-fits-all"** drug.

4. Side Effects and Safety Concerns :

- **Aducanumab & Lecanemab** have raised **safety concerns** (brain swelling, microbleeds) (77).
- **Long-term effects of anti-amyloid therapy** remain unclear.

Future Directions :

- **Combination therapies targeting multiple pathways** (amyloid, tau, inflammation).
- **Precision medicine**—personalized treatment based on **genetics and biomarkers**.
- **Non-invasive biomarkers** (blood tests, retinal scans) to **detect AD earlier**.

5. Emerging Therapeutic Approaches for Alzheimer's Disease :

Current treatments for Alzheimer's disease (AD) are primarily **symptomatic**, but **emerging therapies** aim to **modify disease progression** by targeting **amyloid-beta (Aβ), tau proteins, neuroinflammation, and neurodegeneration**. These include **immunotherapy, tau-targeting therapies, regenerative medicine, and lifestyle interventions**.

5.1. Immunotherapy and Anti-Amyloid Treatments :

Since amyloid-beta (Aβ) accumulation is a key **neuropathological hallmark of AD**, immunotherapy strategies focus on **reducing Aβ plaques and preventing their formation**.

5.1.1 Monoclonal Antibodies (mAbs) Targeting Aβ :

Monoclonal antibodies (mAbs) **bind to amyloid-beta** and promote its **clearance through microglial phagocytosis** or **peripheral sink mechanisms** (16).

Drug	Mechanism of Action	Clinical Status
Aducanumab (Aduhelm)	Removes Aβ plaques via microglial activation	FDA-approved (2021, controversial)
Lecanemab (Leqembi)	Binds to soluble Aβ protofibrils to prevent plaque formation	FDA-approved (2023)
Donanemab	Promotes Aβ clearance by targeting amyloid fibrils	Phase 3 trials
Gantenerumab	Enhances microglial-mediated clearance of Aβ	Discontinued after Phase 3 failure.

Challenges & Limitations :

- **Limited clinical benefits** despite plaque reduction (Knopman et al., 2021).
- **Amyloid-Related Imaging Abnormalities (ARIA)**, including **brain swelling and microhemorrhages** (77).

5.1.2 Active vs. Passive Immunotherapy :

Type	Description	Examples
Active immunotherapy	Stimulates patient's immune system to generate anti-Aβ antibodies	CAD106 (discontinued)
Passive immunotherapy	Exogenous mAbs directly bind Aβ for clearance	Aducanumab, Lecanemab

Active immunotherapies are being reconsidered due to **inflammatory risks** seen in earlier trials (79).

5.2. Tau-Targeting Therapies :

Since tau **neurofibrillary tangles (NFTs)** correlate better with **cognitive decline than Aβ**, **anti-tau therapies** are being developed (80).

5.2.1 Anti-Tau Monoclonal Antibodies :

These antibodies target **extracellular tau aggregates**, preventing their **spread between neurons**.

Drug	Mechanism of Action	Clinical Status
Gosuranemab	Binds extracellular tau to block aggregation	Phase 2
Zagotenemab	Prevents tau propagation	Discontinued
Semorinemab	Reduces extracellular tau spread	Ongoing trials

5.2.2 Small Molecule Inhibitors :

These drugs **inhibit tau hyperphosphorylation and aggregation**.

- **Methylthioninium chloride (Rember)** – targets tau fibrils (81).
- **TRx0237 (LMTX)** – inhibits tau aggregation, mixed results in trials (82).

Challenges :

- Tau pathology occurs **later in AD**, potentially reducing the therapeutic window.
- **Limited blood-brain barrier (BBB) penetration** for some drugs.

5.3. Neuroprotective and Regenerative Therapies :

Since **neurodegeneration is irreversible**, therapies aiming at **cell regeneration and neuroprotection** are being explored.

5.3.1 Stem Cell Therapy :

Stem cell therapy aims to **replace lost neurons and restore synaptic function** (83).

Stem Cell Type	Potential Benefit
Mesenchymal Stem Cells (MSCs)	Reduce neuroinflammation, promote neuroprotection
Neural Stem Cells (NSCs)	Differentiate into neurons, integrate into brain circuits
Induced Pluripotent Stem Cells (iPSCs)	Patient-derived cells for personalized therapy

Current Status :

- **Phase 1/2 trials** show promise in **reducing inflammation** and **improving cognition** (83).
- **Challenges**: Ethical concerns, immune rejection, tumor risk.

5.3.2 Neurotrophic Factors :

Neurotrophic factors like **BDNF (Brain-Derived Neurotrophic Factor)** and **NGF (Nerve Growth Factor)** protect neurons from degeneration.

- **NGF gene therapy (CERE-110)** – Injected directly into the brain; showed **partial cognitive improvement** (84).
- **BDNF therapy** – Under investigation for synaptic repair.

5.4. Lifestyle Interventions and Non-Pharmacological Approaches :

Lifestyle changes **reduce AD risk and slow progression** (18).

5.4.1 Diet and Nutrition :

Certain diets support **brain health and reduce neuroinflammation**.

Diet	Effect on AD
Mediterranean diet	High in antioxidants, reduces cognitive decline
Ketogenic diet	Increases ketones for brain energy, improves cognition
MIND diet	Hybrid of Mediterranean & DASH diets, slows AD progression.

5.4.2 Physical Exercise and Cognitive Training :

Regular exercise enhances **BDNF levels** and **synaptic plasticity** (85).

- **Aerobic exercise** (walking, running) improves **hippocampal volume**.
- **Cognitive training** (puzzles, memory games) enhances **neural connectivity** (86).

Here's a **detailed and well-referenced** section on **Challenges and Future Directions in Alzheimer's Disease (AD) Research and Treatment**, covering **drug development barriers, ethical considerations, and precision medicine**.

6. Challenges and Future Directions in Alzheimer's Disease Research and Treatment :

Despite **significant progress** in understanding the pathophysiology of Alzheimer's disease (AD), **effective disease-modifying treatments remain elusive**. Drug development has been hampered by **high failure rates in clinical trials, ethical concerns, and the complexity of disease heterogeneity**. Emerging strategies, including **precision medicine and personalized therapies**, offer promising future directions.

6.1. Barriers in Drug Development :

6.1.1. High Failure Rates of Clinical Trials :

- **Over 99% of AD drug trials have failed** in the past two decades (15).
- The **long disease course and heterogeneous pathology** make **target identification difficult**.
- Many drugs **effectively reduce amyloid plaques but do not reverse cognitive decline** (16).

Category	Challenges	Example
Amyloid-targeting drugs	Do not always correlate with cognitive improvement	Aducanumab.
Tau-targeting drugs	Limited success in clearing tau tangles	Gosuranemab
Anti-inflammatory drugs	Mixed results in reducing neuroinflammation	NSAIDs failed trials

6.1.2. Blood-Brain Barrier (BBB) Limitations :

- The **BBB restricts drug penetration**, reducing the effectiveness of large-molecule therapies.
- **Gene therapies and monoclonal antibodies** struggle to **cross the BBB efficiently** (87).

6.1.3. Lack of Reliable Biomarkers for Early Detection :

- **CSF and PET biomarkers are promising** but **costly and invasive** (88).
- **Blood-based biomarkers (e.g., p-tau217) are emerging** but **need further validation**.

6.2. Ethical Considerations in AD Research :

6.2.1. Informed Consent and Cognitive Decline :

- AD patients may **lack decision-making capacity** during later disease stages.
- Ethical concerns arise in **clinical trial enrollment** when patients **cannot provide full informed consent** (89).

6.2.2. Use of Placebo in Clinical Trials :

- Placebo-controlled trials may **deny potentially beneficial treatments** to patients.

- Ethical challenges in **testing new therapies against ineffective standards of care** (90).

6.2.3. Genetic Testing and Privacy Concerns :

- **APOE ε4 and other genetic tests** help identify **AD risk** but raise **ethical dilemmas** (91).
- **Concerns over genetic discrimination** in employment and insurance policies.

6.2.4. Diversity and Inclusivity in AD Research :

- **Most AD clinical trials lack diverse racial and ethnic representation** (92).
- Need for **inclusive research** to develop **therapies effective across populations**.

6.3. The Role of Precision Medicine and Personalized Therapies :

6.3.1. Genetic and Molecular Profiling :

- **Advances in genomics and proteomics** allow **personalized treatment strategies** (93).
- Genetic factors such as **APOE ε4, TREM2, and BIN1** influence **AD progression and drug response**.

6.3.2. AI and Machine Learning in Drug Discovery :

- AI-based models can **analyze vast datasets** to identify **novel drug targets** (94).
- Machine learning aids in **early diagnosis and disease progression prediction**.

6.3.3. Future of Gene Therapy and RNA-Based Treatments :

- **CRISPR and antisense oligonucleotides (ASOs)** are being tested for **targeted gene modification**.
- **Targeting tau or APOE ε4 using RNA therapies** may provide future treatments (95).

Conclusion:

Alzheimer's disease remains one of the most significant healthcare challenges of the 21st century, affecting millions of individuals worldwide. Despite extensive research, a definitive cure is yet to be found, and available treatments primarily manage symptoms rather than halt disease progression. However, recent advancements in anti-amyloid therapies, tau-targeting treatments, and regenerative medicine present promising avenues for future interventions. Early diagnosis through biomarker detection and AI-driven diagnostics can enhance treatment efficacy and patient outcomes. Additionally, lifestyle modifications, including a healthy diet, physical exercise, and cognitive engagement, may help reduce the risk of AD. Moving forward, interdisciplinary research and innovative therapeutic strategies will be crucial in developing effective interventions to slow or prevent AD progression, ultimately improving the quality of life for affected individuals and their caregivers.

REFERENCES:

1. Alzheimer's Association. (2023). *2023 Alzheimer's Disease Facts and Figures*. *Alzheimer's & Dementia, 19*(4), 1598-1701.
2. Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chetelat, G., Teunissen, C. E., ... & van der Flier, W. M. (2021). Alzheimer's disease. *The Lancet, 397*(10284), 1577-1590.
3. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., ... & Pericak-Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. *Science, 261*(5123), 921-923.
4. Hardy, J., & Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science, 256*(5054), 184-185.
5. Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer's disease. *New England Journal of Medicine, 362*(4), 329-344.

6. van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Sims, J. R. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine, 388*(1), 9-21.
7. Alzheimer, A. (1907). Über eine eigenartige Erkrankung der Hirnrinde. *Allgemeine Zeitschrift für Psychiatrie und psychisch-gerichtliche Medizin, 64*, 146–148.
8. Kraepelin, E. (1910). *Psychiatrie: Ein Lehrbuch für Studierende und Ärzte* (8th ed., Vol. III). Barth.
9. Blessed, G., Tomlinson, B. E., & Roth, M. (1968). The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. *British Journal of Psychiatry, 114*(512), 797-811.
10. Alzheimer's Disease International (ADI). (2021). *Dementia statistics*. Retrieved from https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
11. GBD 2019 Dementia Collaborators. (2021). Estimation of the global prevalence, incidence, and burden of Alzheimer's disease and other dementias. *The Lancet Neurology, 20*(12), 965–975. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588915/
12. Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. *Science, 217*(4558), 408-414.
13. Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., ... & Silverberg, N. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's & Dementia, 14*(4), 535-562. https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2018.02.018
14. Kunkle, B. W., Grenier-Boley, B., Sims, R., Bis, J. C., Damotte, V., Naj, A. C., ... & Alzheimer's Disease Genetics Consortium. (2019). Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. *Nature Genetics, 51*(3), 414-430. https://www.nature.com/articles/s41588-019-0358-2
15. Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack Jr, C. R., Jones, R. W., ... & Scheltens, P. (2022). Drug development in Alzheimer's disease: The path to 2025. *Alzheimer's Research & Therapy, 14*(1), 1-29. https://alzres.biomedcentral.com/articles/10.1186/s13195-022-01059-0
16. van Dyck, C. H., et al. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine, 388*(9), 9-21.
17. Li, Y., He, M., Zhang, X., & Bai, G. (2022). Stem cell therapy for Alzheimer's disease. *Frontiers in Aging Neuroscience, 14*, 937486. https://www.frontiersin.org/articles/10.3389/fnagi.2022.937486/full
18. Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., ... & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet, 396*(10248), 413-446. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30367-6/fulltext
19. Ngandu, T., Lehtisalo, J., Solomon, A., Levälahti, E., Ahtiluoto, S., Antikainen, R., ... & Kivipelto, M. (2015). A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. *The Lancet, 385*(9984), 2255-2263. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60461-5/fulltext
20. Nichols, E., Steinmetz, J. D., Vollset, S. E., Fukutaki, K., Chalek, J., Abd-Allah, F., ... & Vos, T. (2022). Estimating the global prevalence of dementia: A systematic review and meta-analysis. *The Lancet Public Health, 7*(2), e105-e125. https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext
21. Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., Prina, M., Winblad, B., Jönsson, L., & Prince, M. (2020). The worldwide costs of dementia in 2019. *Alzheimer's & Dementia, 16*(10), 1315–1323. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12166
22. Hardy, J., & Higgins, G. (1992). Alzheimer's disease: the amyloid cascade hypothesis. *Science, 256*(5054), 184-185.
23. Heneka, M. T., et al. (2015). Neuroinflammation in Alzheimer's disease. *Lancet Neurology, 14*(4), 388-405.
24. Reisberg, B., et al. (2003). Memantine in moderate-to-severe Alzheimer's disease. *New England Journal of Medicine, 348*(14), 1333-1341.
25. Corder, E. H., et al. (1993). Gene dose of APOE type 4 allele and risk of Alzheimer's disease. *Science, 261*(5123), 921-923
26. Petersen, R. C., et al. (1999). Mild cognitive impairment. *Archives of Neurology, 56*(3), 303-308.
27. Albert, M. S., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease. *Alzheimer's & Dementia, 7*(3), 270-279.
28. Blennow, K., et al. (2010). CSF biomarkers in Alzheimer's disease. *Nature Reviews Neurology, 6*(3), 131-144.WHO. (2023). *Dementia fact sheet*. Retrieved from https://www.who.int/news-room/fact-sheets/detail/dementia
29. Frisoni, G. B., et al. (2010). The clinical use of structural MRI in Alzheimer's disease. *Nature Reviews Neurology, 6*(2), 67-77.
30. Clark, C. M., et al. (2012). Use of florbetapir-PET for imaging β-amyloid pathology. *JAMA, 308*(8), 885-895.
31. Mosconi, L., et al. (2008). Hypometabolism in AD and risk assessment. *Journal of Nuclear Medicine, 49*(2), 210-217.
32. Schindler, S. E., et al. (2019). Blood biomarkers of Alzheimer's disease. *Neurology, 93*(24), e2230-e2240.
33. Janelidze, S., et al. (2020). Plasma p-tau181 in Alzheimer's disease. *Nature Medicine, 26*(3), 379-386.
34. Zetterberg, H., et al. (2016). Blood-based biomarkers for Alzheimer's disease. *Molecular Neurodegeneration, 11*(1), 5.

35. Birks, J. (2006). Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database of Systematic Reviews, 2006*(1), CD005593.
36. Tariot, P. N., et al. (2004). Memantine treatment in moderate to severe Alzheimer's disease. *Journal of the American Medical Association, 291*(3), 317-324.
37. Salloway, S., et al. (2022). Amyloid-related imaging abnormalities in Alzheimer's disease. *Alzheimer's & Dementia, 18*(5), 848-858.
38. De Strooper, B., & Karran, E. (2016). The cellular phase of Alzheimer's disease. *Cell, 164*(4), 603-615.
39. Gauthier, S., et al. (2016). Alzheimer's disease: New horizons in prevention and treatment. *Alzheimer's Research & Therapy, 8*(1), 1-12.
40. Erickson, K. I., et al. (2011). Exercise training increases size of hippocampus and improves memory. *PNAS, 108*(7), 3017-3022.
41. Ballard, C., et al. (2019). Dementia prevention, intervention, and care. *The Lancet, 390*(10113), 2673-2734.
42. Pardridge, W. M. (2020). Drug transport across the blood-brain barrier. *Journal of Cerebral Blood Flow & Metabolism, 40*(1), 12-24.
43. Hansson, O., et al. (2021). Blood biomarkers for Alzheimer's disease. *Nature Reviews Neurology, 17*(5), 261-272.
44. Karlawish, J. (2021). The problem of Alzheimer's: How science, culture, and politics turned a rare disease into a crisis. *St. Martin's Press.*
45. Snyder, H. M., et al. (2022). Ethical challenges in Alzheimer's disease research. *Alzheimer's & Dementia, 18*(8), 1508-1516.
46. Bird, T. D. (2020). Genetic aspects of Alzheimer's disease. *Genetics in Medicine, 22*(3), 1-10.
47. Gilmore-Bykovskyi, A., et al. (2021). Inclusion of underrepresented racial and ethnic groups in Alzheimer's disease research. *JAMA Neurology, 78*(12), 1503-1511Brodaty, H., & Donkin, M. (2009). Family caregivers of people with dementia. *Dialogues in Clinical Neuroscience, 11*(2), 217–228. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181916/
48. Hampel, H., O'Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., & Blennow, K. (2021). Blood-based biomarkers for Alzheimer's disease: Mapping the road to the clinic. *Nature Reviews Neurology, 17*(7), 327-338. https://www.nature.com/articles/s41582-021-00542-3
49. Tao, Q., et al. (2021). Artificial intelligence applications in Alzheimer's disease. *Nature Machine Intelligence, 3*(3), 174-186.
50. De Strooper, B., & Karran, E. (2021). The cellular phase of Alzheimer's disease. *Cell, 184*(3), 603-615.

How to cite this article:
Anshika Sharma et al. Ijppr.Human, 2025; Vol. 31 (4): 361-376.

Conflict of Interest Statement: All authors have nothing else to disclose.